GMP Lifecycle, Data Integrity & Supply Chain | Edition 33
GMP and GDP update covering lifecycle control, data integrity, reference samples, AI in GMP, medicine shortages and supply-chain integrity.
GXP COMPLIANCE NEWSLETTER
Kyle Winn and Adam Walker
6/26/202611 min read
Help Me GxP
Prepared for publication: 26 June 2026
Source window: 19 June to 26 June 2026
Focus: UK, EU and United States GMP / GDP
INTRODUCTION
This edition has a clear theme: control across the product lifecycle. The most useful signals this week sit across regulatory decision-making, clinical-trial governance, reference and retention samples, AI in GMP, shortage prevention planning, and online supply-chain integrity.
There were fewer verified medicine recall and defect items in the strict 7-day window, so that section is intentionally short. That is not a sign that quality risk has disappeared. It simply means this edition does not pad the recall section with older or weaker items.
This newsletter is educational. It supports awareness, discussion and professional development. It does not replace site-specific procedures, formal training, Pharmaceutical Quality Systems, Quality review, Responsible Person judgement, Qualified Person decisions, or regulatory advice.
FROM HELP ME GxP
Help Me GxP continues to focus on practical GMP and GDP education for people working across quality, manufacturing, distribution, pharmacy, aseptic services, validation, regulatory affairs and supply-chain roles.
This week’s edition keeps the newer format: shorter source window, more current updates, no forced item count, and a plain overview for each story. The aim is to make the newsletter useful for busy professionals without losing source discipline or regulatory caution.
This edition is sponsored by W2 Cleanroom Consulting. W2 supports pharma, biotech and healthcare organisations with cleanroom design, validation and compliance support, helping teams plan controlled environments and maintain practical evidence for regulated operations.
Sponsor: www.w2cleanrooms.com
NEWS IN PHARMA
Six meaningful verified items were identified for this section during the coverage window.
1. EU: CHMP June meeting recommends six new medicines for approval
Overview:
EMA reported that the CHMP recommended six new medicines for approval at its 22-25 June 2026 meeting, including Aujemflu, Hopledo, Onswik, two biosimilars and Daybu following re-examination with a restricted indication. The committee also recommended extensions of therapeutic indication for 12 authorised medicines.
For GxP teams, CHMP outcomes are not only regulatory news. New authorisations, biosimilars and indication extensions all create downstream responsibilities for product information, manufacturing control, supply planning, pharmacovigilance, distribution readiness and lifecycle change management.
Source:
2. EU: EMA recommends revoking Tavneos marketing authorisation
Overview:
EMA announced that the CHMP has recommended revoking the marketing authorisation for Tavneos in the EU because its benefits are no longer proven to outweigh its risks. The review was initiated after information raised questions about data integrity in the main study supporting the authorisation.
This is a strong reminder that lifecycle confidence depends on reliable clinical and regulatory evidence. Data integrity and good clinical practice failures can have direct product-availability consequences, and the downstream impact reaches clinicians, patients, supply chains and governance teams.
Source:
https://www.ema.europa.eu/en/news/ema-recommends-revoking-marketing-authorisation-tavneos
3. UK: MHRA update on the PATHWAYS clinical trial
Overview:
MHRA published an update on the PATHWAYS clinical trial on 19 June 2026, confirming that scientific dialogue with the trial sponsor had concluded and that a modified protocol had been agreed as meeting regulatory standards. The update also notes strengthened safeguards, including clearer discontinuation measures and additional participant information.
Although this is a clinical-trial update rather than a manufacturing signal, it remains relevant to GxP because investigational work depends on controlled protocols, documented decisions, participant protection, ethical approval and evidence-led governance. Weakness in trial design or control can undermine later regulatory confidence.
Source:
https://www.gov.uk/government/news/update-on-the-pathways-clinical-trial
4. EU: COMBINE programme launches phase 2 of the coordinated assessment pilot
Overview:
The European Commission announced phase 2 of the COMBINE coordinated assessment pilot for combined studies. The expanded phase covers multinational investigational medicinal product clinical trials combined with IVD performance studies or medical device clinical investigations, including possible ATMP studies.
This is relevant where medicinal products, devices, diagnostics and clinical operations meet. For sponsors, manufacturers and quality teams, combined studies increase the need for clear interfaces, controlled documentation, accountability, change management and joined-up regulatory submissions.
Source:
https://ec.europa.eu/newsroom/sante/newsletter-archives/76937
5. UK: MHRA orphan register updated
Overview:
MHRA updated the UK orphan registered medicinal products page on 26 June 2026. The update includes an addition to the orphan register for Koselugo 5 mg and 7.5 mg granules in capsule for opening.
Product-register updates are not routine background noise. They are part of lifecycle control and can affect product information, presentation management, supply considerations and the way teams track authorised products and changes over time.
Source:
https://www.gov.uk/government/publications/orphan-registered-medicinal-products
6. EU: CHMP starts Rifadin referral over excipient concerns
Overview:
In the June CHMP highlights, EMA reported the start of a review of Rifadin 20 mg/ml oral suspension and syrup following concerns about the levels of diethanolamine, an excipient classified as a possible carcinogen based on long-term high-dose animal exposure.
For pharmaceutical quality teams, this is a useful reminder that excipients are not passive ingredients from a control perspective. Excipient levels, specifications, supplier controls, toxicological assessments, formulation history and regulatory commitments all need to remain visible throughout the product lifecycle.
Source:
NEWS IN DISTRIBUTION
Only three meaningful verified distribution items were identified in the strict 7-day window, so this section is intentionally shorter.
1. EU: EMA shortage prevention plan workshop held online
Overview:
EMA held an online Shortage Prevention Plan workshop on 22 June 2026 for nominated participants from eligible pharmaceutical industry associations. The workshop covered proposed updates to the Shortage Prevention Plan template and guidance, including changes linked to the new pharmaceutical legislation and lessons from the 2025 SPP and SMP pilot.
This is directly relevant to distribution and supply continuity. Shortage prevention depends on timely data, clear escalation routes, realistic supply-risk assessments, and the ability to provide requested information to regulators when vulnerabilities in supply become visible.
Source:
https://www.ema.europa.eu/en/events/shortage-prevention-plan-spp-workshop
2. EU: Tavneos recommendation creates potential treatment-transition and supply-control implications
Overview:
EMA states that, if the European Commission confirms the recommendation to revoke Tavneos, the medicine will no longer be authorised in the EU. CHMP also recommends that no new patients should start treatment and that existing patients should be switched to suitable alternatives.
For distribution teams and responsible supply-chain functions, market authorisation changes can quickly become stock-control, communication and traceability questions. The practical issue is not only whether product can be supplied, but whether supply remains appropriate, authorised and aligned with current regulatory decisions.
Source:
https://www.ema.europa.eu/en/news/ema-recommends-revoking-marketing-authorisation-tavneos
3. US: FDA warning letters highlight online access to unapproved drug products
Overview:
FDA’s warning letter page shows a cluster of CDER warning letters posted on 23 June 2026 for unapproved new drugs and misbranded products. The listed firms include several online sellers and product providers, with letters issued on 17 June 2026.
This is relevant to distribution because supply-chain integrity is not only about licensed wholesalers. Online access, unapproved products, misbranding and non-authorised routes all create patient-risk pathways outside the controlled medicines supply chain.
Source:
GMP / GDP REGULATORY NEWS
Five meaningful verified items were identified for this section during the coverage window.
1. EU: EudraLex Volume 4 Reference and Retention Samples revised
Overview:
The European Commission published a revised EudraLex Volume 4 document on Reference and Retention Samples on 24 June 2026. The page states that the revised document is applicable as of 24 September 2026.
This is a practical GMP signal. Reference and retention samples are often treated as storage requirements, but they are also part of investigation capability, product traceability, market-action readiness, and the ability to support complaints, suspected defects and regulatory enquiries.
Source:
2. EU: EMA prepares Annex 22 workshop on AI in GMP
Overview:
EMA’s GMP/GDP Inspectors Working Group is organising a two-day workshop on 30 June and 1 July 2026 to gather expert opinion and evidence for EU guidance on artificial intelligence in medicines manufacturing, referred to as Annex 22.
The workshop is highly relevant to GMP because it addresses the responsible use of AI technologies in manufacturing, including data governance, model evaluation, transparency, accountability, human oversight, validation, lifecycle management, cybersecurity and outsourced activities.
Source:
3. UK: MHRA Innovation Office guidance updated
Overview:
MHRA updated its Innovation Office guidance and support page on 25 June 2026. The page explains that the Innovation Office supports questions on products or technologies that challenge the current regulatory framework, especially where development is early or regulatory uncertainty exists.
For GxP organisations working with novel technologies, the lesson is to avoid treating innovation as a reason to bypass evidence. Early regulatory engagement, clear problem statements and controlled development strategies are part of credible innovation in regulated environments.
Source:
https://www.gov.uk/government/publications/mhra-innovation-office-guidance-and-support
4. US: FDA posts multiple CDER warning letters on unapproved new drugs
Overview:
FDA’s warning-letter listing shows multiple CDER letters posted on 23 June 2026, several with the subject unapproved new drugs or misbranded products. The page also reminds readers that matters described in warning letters may be subject to later interaction between FDA and recipients.
For regulatory and quality teams, warning letters are useful signals because they show how regulators frame risk and non-compliance. They should not be overread as final legal determinations beyond the letter, but they can support internal horizon scanning and supplier or market-risk awareness.
Source:
5. EU: Tavneos review links regulatory decision-making to GCP and data integrity
Overview:
EMA states that the Tavneos review was initiated after questions were raised about data integrity in the Advocate study, and that CHMP concluded the study had been conducted in breach of good clinical practice principles. EMA says the data could no longer be relied upon for demonstrating effectiveness.
Although this is not a GMP finding, it is squarely within GxP. It shows that data integrity is not a documentation slogan. If critical data cannot be relied on, the consequence can reach authorisation status, product availability and patient treatment pathways.
Source:
https://www.ema.europa.eu/en/news/ema-recommends-revoking-marketing-authorisation-tavneos
PHARMA RECALLS AND QUALITY DEFECTS
No new meaningful licensed-medicine recall or quality-defect items were identified from the checked official UK and US public pages within the strict 19 June to 26 June 2026 window. This section is therefore intentionally short rather than padded with older recalls.
1. UK: No new MHRA medicine recall or defect notification identified in the 7-day window
Overview:
The MHRA alerts page was checked during this edition. The most recent medicine recall or notification visible in the checked listing was the Class 3 recall for Orbit Pharma Limited Cyclizine Lactate 50 mg/ml Solution for injection, issued on 16 June 2026, which falls outside this edition’s 7-day window.
That recall was not included as a current item because this edition is using a strict source window. This is deliberate source discipline: if the evidence does not support a current recall item, the newsletter should say so rather than backfilling with older content.
Source:
https://www.gov.uk/drug-device-alerts
2. US: No FDA-posted drug recall announcement identified in the 7-day window
Overview:
The FDA Recalls, Market Withdrawals and Safety Alerts page was checked for current public recall postings. In the checked listing, the items dated 22-25 June 2026 were food or animal-related, while the latest visible drug item was dated 12 June 2026, outside this edition’s strict 7-day window.
FDA also states that not all recalls have press releases or are posted on this page, so this should not be interpreted as proof that no recall activity exists anywhere in the system. It only reflects the checked public source used for this newsletter.
Source:
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
GDP / SUPPLY-CHAIN SIGNALS
Four meaningful verified GDP or supply-chain integrity signals were identified in the strict 7-day window.
1. US: FDA warning letter to Wholesale Peptide highlights unapproved injectable products
Overview:
FDA issued a warning letter to Wholesale Peptide dated 17 June 2026 and posted within this edition’s source window. FDA states that a website review found Prostamax and Gonadorelin to be unapproved new drugs, and that injectable products are especially concerning because they bypass some of the body’s key defences against toxins and microorganisms.
This is a strong supply-chain integrity signal. Products offered outside authorised pathways can create direct patient risk, especially where injectable administration, unclear quality controls, poor sterility assurance or unverified sourcing are involved.
Source:
2. US: FDA warning letter to Leading Edge Health identifies unapproved new drug concerns
Overview:
FDA issued a warning letter to Leading Edge Health dated 17 June 2026 and posted during this edition’s source window. FDA states that Erectin Stimulating Gel and VigRX Delay Wipes were unapproved new drugs based on review of the company’s website.
From a GDP and supply-chain perspective, the signal is the same: medicines-related products marketed outside authorised controls can undermine patient protection. Supply-chain assurance depends on authorised products, legitimate sources, accurate product claims and clear regulatory status.
Source:
3. EU: Shortage prevention planning moves further into structured data expectations
Overview:
The EMA Shortage Prevention Plan workshop covered proposed updates to the SPP template and guidance, including the timeline and data elements that companies may need to provide to authorities under upcoming legislation.
For GDP teams, shortage prevention is not just a commercial planning activity. It links to stock visibility, customer communication, batch traceability, demand/supply assumptions, transport capacity and the governance needed to escalate risk before patients are affected.
Source:
https://www.ema.europa.eu/en/events/shortage-prevention-plan-spp-workshop
4. EU: Tavneos recommendation shows the supply impact of lifecycle regulatory decisions
Overview:
EMA’s Tavneos communication includes clear advice that no new patients should start treatment and that existing patients should be switched to suitable alternatives. If the recommendation is confirmed, Tavneos will no longer be authorised in the EU.
This is a useful GDP reminder because authorisation status, stock status and supply status must remain aligned. Distribution controls should be able to respond to changes in regulatory status, market action, medical advice and patient-risk communication.
Source:
https://www.ema.europa.eu/en/news/ema-recommends-revoking-marketing-authorisation-tavneos
UPCOMING CONFERENCES AND TRAINING
1. EMA GMP Annex 22 AI workshop
Date: 30 June and 1 July 2026
Location: Online and EMA, Amsterdam
Overview:
EMA’s GMP/GDP Inspectors Working Group is holding a two-day workshop to gather expert input for Annex 22, the planned EU guidance on AI in medicines manufacturing. The first day is an open session, with invited active participation and a live broadcast for interested viewers.
This is one of the most relevant upcoming GMP events for teams considering AI in regulated activities. It covers topics that should already be familiar to quality teams: validation, lifecycle management, human oversight, accountability, cybersecurity and outsourced activities.
Source:
2. FDA CDER SBIA Learn
Date: ongoing learning resource, with upcoming July 2026 events listed
Location: Online
Overview:
FDA’s CDER SBIA Learn page lists training resources, webinars, recordings, online courses, newsletters and podcasts. The page includes topic filters relevant to GxP professionals, including cGMP, CMC, inspections, supply chain, DSCSA, distributors and wholesalers.
For teams working with US expectations, this is a useful official training hub rather than a single event. It can support awareness of FDA terminology, regulatory processes and recurring themes that may affect pharmaceutical quality and supply-chain work.
Source:
AUDIT READINESS TIP
Theme: Reference and retention samples are evidence, not just stored material.
The revised EudraLex Volume 4 update on reference and retention samples is a useful prompt for internal audit planning. These samples are often physically present but weakly governed: unclear ownership, weak storage evidence, poor retrieval testing, incomplete traceability, or uncertainty over responsibilities where manufacturing, importation, testing and batch release are split between organisations.
Practical checks for your next audit:
Can staff explain the difference between reference samples and retention samples in your system?
Are quantities, storage conditions, retention periods and responsibilities defined in approved procedures?
Can one batch be traced from retained sample location back to batch documentation, release decision, market destination and any complaint or defect history?
Do contracts and technical agreements define sample responsibilities where work is outsourced?
Are sample excursions, damage, missing samples or retrieval failures investigated as quality events?
Has the site tested how quickly samples can be retrieved during a complaint, defect investigation or regulatory request?
A retained sample that cannot be located, identified, protected or linked to reliable records is not a control. It is just stock on a shelf.
Source:
GxP FACT
A quiet recall section does not prove a quiet quality system.
FDA states that not all recalls have press releases or are posted on its Recalls, Market Withdrawals and Safety Alerts page. That matters for newsletter writing and for quality systems: public recall pages are useful signals, but they are not the whole recall universe.
For regulated organisations, the better question is whether internal systems can detect, escalate, investigate and act on quality signals quickly, even before a public recall page is updated.
Source:
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
CALL TO ACTION
This edition was intentionally tighter and more selective. A 7-day window means fewer items in some sections, but it also keeps the newsletter current and avoids padding.
If this edition is useful, share it with colleagues in QA, QC, Production, Warehouse, Distribution, Regulatory Affairs, Responsible Person teams, QPs, pharmacists, aseptic services and supply-chain roles.
Help Me GxP will continue to cover GMP and GDP together because product quality does not stop at manufacture, release or dispatch.
This edition is sponsored by W2 Cleanroom Consulting: www.w2cleanrooms.com
Kyle Winn / Adam Walker
Help Me GxP
HASHTAGS
#GxP #GMP #GDP #Pharma #QualityAssurance #MHRA #EMA #FDA #PharmaceuticalManufacturing #PharmaceuticalDistribution #SupplyChainIntegrity #InspectionReadiness #PatientSafety
Contact
Get in touch
info@w2cleanrooms.com
© 2026. All rights reserved.
Our Brands
Free GxP Training
